Intuitive Surgical Stock Has Been Hit Hard in 2026. Is It Finally Time to Buy?

Intuitive Surgical shares are down about 26% in 2026 and nearly a third from a January peak above $600, but the underlying business remains strong. Q1 revenue rose 23% year over year to $2.77 billion, procedures increased 17%, adjusted EPS jumped 38%, and management raised full-year da Vinci procedure growth guidance to 13.5%-15.5%. The article argues China competition is a real but limited risk, while fears that OpenAI will disrupt robotic surgery are likely overstated.

Analysis

The market is treating AI as an existential threat to surgical robotics, but that’s a category error: humanoid/general-purpose robotics can commoditize perception and motion control, yet soft-tissue surgery is dominated by workflow integration, regulatory trust, surgeon training, and installed-base data. That means the near-term loser from OpenAI’s robotics push is not ISRG, but lower-quality private medtech entrants and China-linked imitators that may face an even higher bar if capital starts rewarding “AI robotics” narratives over proven clinical platforms.

The more interesting second-order effect is on margins and mix. ISRG’s recurring consumables stream and growing attach rates make it unusually resilient to macro noise, but tariff, freight, and memory inflation can still compress the operating leverage investors have been underwriting. If procedure growth merely tracks the mid-teens while per-case revenue keeps edging up, the stock can de-risk fundamentals even if headline multiple expansion is capped; if GLP-1 pressure broadens beyond bariatrics into adjacent abdominal procedures, the market will start to haircut long-duration growth assumptions.

Consensus appears to be overestimating China and underestimating duration risk. China is real, but it is a localized share-and-pricing issue; the bigger valuation risk is that a 50x+ earnings multiple leaves little cushion if 2027 growth normalizes one or two points lower or if input-cost inflation persists for several quarters. The stock looks more like a high-quality compounder with a poor entry point than a broken story, which argues for tactical rather than full-size exposure.

Catalyst-wise, the next 1-2 quarters matter more than the next 1-2 years: another guide-up or continued acceleration in installed-base monetization can force a squeeze in short-duration bearish positioning, while any procedure deceleration in U.S. elective categories would quickly validate the bears. The likely reversal path for the selloff is not an AI clarification headline; it is steady proof that AI is helping ISRG widen its moat through data, software, and surgeon workflow rather than opening the door to substitutes.

Key Decisions for Investors

• Tactically buy ISRG on weakness only if it holds above the recent lows into the next print; risk/reward is acceptable for a 3-6 month trade only if the market stops discounting an AI disruption premium to zero, with upside toward a partial multiple re-rate if guide-up continues.
• Pair trade: long ISRG / short a basket of lower-quality medtech robotics or China-facing surgical automation names for 2-4 quarters; thesis is that the market will re-separate proven installed-base monetizers from narrative-driven competitors.
• Avoid chasing on a full position size at ~50x earnings; use a starter allocation or call spreads rather than outright shares, since the valuation can compress 15-20% on any guide miss even if fundamentals remain intact.
• Add NVDA only as a second-order beneficiary of healthcare AI/robotics infrastructure, not as a direct trade on ISRG weakness; if AI tools are adopted inside surgical workflows, compute and edge-sensing demand could rise, but timing is years not months.
• Watch for a catalyst-driven hedge: if bariatric or broader elective procedure data softens over the next 1-2 quarters, short-dated ISRG puts or put spreads become attractive because the stock’s downside is more valuation-sensitive than fundamentals-sensitive.